Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 55,200 Rigel Pharmaceuticals, Inc. $RIGL

Key Points

• Universal Beteiligungs bought 55,200 shares of Rigel Pharmaceuticals in Q4 (about $2.36 million), representing a 0.30% stake, while other institutional investors also added positions and institutions now own 66.23% of the stock.
• Director Walter H. Moos sold 4,000 shares on Feb. 20 at $36.36 (reducing his holding by 23.92%), and corporate insiders collectively own 10.47% of Rigel.
• Analysts are split (three Buy, three Hold) with a consensus rating of “Moderate Buy” and an average price target of $45.67; the company recently missed EPS ($1.14 vs. $1.33 estimate) though revenue beat, and the stock trades with a market cap of ~$543M and a PE of 1.55.

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 55,200 shares of the biotechnology company's stock, valued at approximately $2,364,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.30% of Rigel Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Beacon Harbor Wealth Advisors Inc. bought a new stake in Rigel Pharmaceuticals during the third quarter worth about $4,310,000. Hennion & Walsh Asset Management Inc. bought a new stake in Rigel Pharmaceuticals during the fourth quarter worth about $2,235,000. Alps Advisors Inc. bought a new stake in Rigel Pharmaceuticals during the third quarter worth about $578,000. Ritholtz Wealth Management increased its stake in Rigel Pharmaceuticals by 961.3% during the 4th quarter. Ritholtz Wealth Management now owns 80,593 shares of the biotechnology company's stock valued at $3,452,000 after purchasing an additional 72,999 shares in the last quarter. Finally, LSV Asset Management increased its stake in Rigel Pharmaceuticals by 15.9% during the 3rd quarter. LSV Asset Management now owns 110,900 shares of the biotechnology company's stock valued at $3,142,000 after purchasing an additional 15,200 shares in the last quarter. 66.23% of the stock is owned by institutional investors.

Insider Activity at Rigel Pharmaceuticals

In other news, Director Walter H. Moos sold 4,000 shares of Rigel Pharmaceuticals stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $36.36, for a total value of $145,440.00. Following the completion of the sale, the director directly owned 12,722 shares in the company, valued at $462,571.92. The trade was a 23.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.47% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on RIGL shares. Weiss Ratings restated a "hold (c+)" rating on shares of Rigel Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. Zacks Research upgraded shares of Rigel Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 18th. Finally, Citigroup restated a "buy" rating on shares of Rigel Pharmaceuticals in a research note on Wednesday, January 14th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.67.

Rigel Pharmaceuticals Stock Performance

Shares of RIGL stock opened at $29.40 on Friday. The company has a 50 day moving average price of $29.53 and a 200-day moving average price of $35.45. Rigel Pharmaceuticals, Inc. has a 52 week low of $16.88 and a 52 week high of $52.24. The firm has a market capitalization of $543.31 million, a PE ratio of 1.55 and a beta of 1.21. The company has a quick ratio of 2.30, a current ratio of 2.42 and a debt-to-equity ratio of 0.06.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.14 EPS for the quarter, missing analysts' consensus estimates of $1.33 by ($0.19). Rigel Pharmaceuticals had a return on equity of 79.84% and a net margin of 124.72%.The company had revenue of $69.80 million during the quarter, compared to the consensus estimate of $68.70 million. As a group, equities research analysts expect that Rigel Pharmaceuticals, Inc. will post 4.25 earnings per share for the current year.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel's lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).

Want to see what other hedge funds are holding RIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.